MX2019004207A - Un metodo de diagnostico complementario para el uso en el tratamiento del sindrome de intestino irritable con dietas de intervencion o trasplante de microbiota fecal. - Google Patents

Un metodo de diagnostico complementario para el uso en el tratamiento del sindrome de intestino irritable con dietas de intervencion o trasplante de microbiota fecal.

Info

Publication number
MX2019004207A
MX2019004207A MX2019004207A MX2019004207A MX2019004207A MX 2019004207 A MX2019004207 A MX 2019004207A MX 2019004207 A MX2019004207 A MX 2019004207A MX 2019004207 A MX2019004207 A MX 2019004207A MX 2019004207 A MX2019004207 A MX 2019004207A
Authority
MX
Mexico
Prior art keywords
treatment
ibs
bowel syndrome
irritable bowel
diagnostic method
Prior art date
Application number
MX2019004207A
Other languages
English (en)
Inventor
Terje Hegge Finn
Casen Christina
Valeur Jørgen
Røseth Arne
Cvancarova Småstuen Milada
Original Assignee
Genetic Analysis As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Analysis As filed Critical Genetic Analysis As
Publication of MX2019004207A publication Critical patent/MX2019004207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/10—Enterobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un método de diagnóstico que puede ser utilizado para determinar la probabilidad de que un sujeto con Síndrome del Intestino Irritable (SII) responderá al tratamiento con un dieta de intervención SII o trasplante de microbiota fecal (TMF). En particular, el método puede ser usado para predecir o determinar la probabilidad de que, una respuesta positiva del sujeto con SII con el tratamiento con una dieta de intervención para SII o el TMF, especialmente para determinar la probabilidad de que la dieta de intervención o el TMF pueden tener un efecto positivo (es decir, beneficioso) en el tracto GI del sujeto, específicamente la microbiota del tracto GI, u otros síntomas o complicaciones del SII (por ejemplo, reducción de la gravedad de los mismos). El método de la presente invención se basa en el análisis de la abundancia de ciertas bacterias en las muestras del tracto GI, por ejemplo, por análisis de ácidos nucleicos.
MX2019004207A 2016-10-14 2017-10-13 Un metodo de diagnostico complementario para el uso en el tratamiento del sindrome de intestino irritable con dietas de intervencion o trasplante de microbiota fecal. MX2019004207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1617519.2A GB201617519D0 (en) 2016-10-14 2016-10-14 A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
PCT/EP2017/076261 WO2018069538A1 (en) 2016-10-14 2017-10-13 A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant

Publications (1)

Publication Number Publication Date
MX2019004207A true MX2019004207A (es) 2019-09-26

Family

ID=57680683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004207A MX2019004207A (es) 2016-10-14 2017-10-13 Un metodo de diagnostico complementario para el uso en el tratamiento del sindrome de intestino irritable con dietas de intervencion o trasplante de microbiota fecal.

Country Status (10)

Country Link
US (3) US10794909B2 (es)
EP (1) EP3526340B1 (es)
JP (1) JP7100045B2 (es)
CN (1) CN110114471A (es)
AU (1) AU2017342088B2 (es)
BR (1) BR112019007424A2 (es)
CA (1) CA3039144A1 (es)
GB (1) GB201617519D0 (es)
MX (1) MX2019004207A (es)
WO (1) WO2018069538A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111261238A (zh) * 2020-01-15 2020-06-09 生态环境部南京环境科学研究所 PPCPs类有机化学品中温厌氧消化去除率预测模型的构建方法
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
CN114686557A (zh) * 2022-03-07 2022-07-01 中国农业大学 用于评估食物过敏的肠道菌群生物标志物及其用途和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709728D0 (en) 1997-05-13 1997-07-02 Dynal As Single step method
GB0001450D0 (en) 2000-01-21 2000-03-08 Genpoint As Cell isolation method
AU2006306241B9 (en) 2005-10-24 2012-03-08 Nestec S.A. Dietary fiber formulation and method of administration
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
GB201021399D0 (en) * 2010-12-16 2011-01-26 Genetic Analysis As Oligonucleotide probe set and methods of microbiota profiling
EP3686284A1 (en) * 2012-05-18 2020-07-29 Genome Research Limited Methods and groups
WO2015171493A1 (en) * 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
JP7182872B2 (ja) 2014-10-29 2022-12-05 グリコム・アクティーゼルスカブ 過敏性腸症候群の治療のための合成組成物および方法
GB201505364D0 (en) 2015-03-27 2015-05-13 Genetic Analysis As Method for determining gastrointestinal tract dysbiosis
CN105543385A (zh) 2016-01-29 2016-05-04 山东大学齐鲁医院 肠易激综合征微生物标志物及其应用

Also Published As

Publication number Publication date
US20220120747A1 (en) 2022-04-21
AU2017342088B2 (en) 2023-11-16
CA3039144A1 (en) 2018-04-19
RU2762266C1 (ru) 2021-12-17
EP3526340B1 (en) 2024-06-26
WO2018069538A1 (en) 2018-04-19
GB201617519D0 (en) 2016-11-30
US10794909B2 (en) 2020-10-06
EP3526340A1 (en) 2019-08-21
AU2017342088A1 (en) 2019-05-02
US20200400666A1 (en) 2020-12-24
US20200049708A1 (en) 2020-02-13
JP7100045B2 (ja) 2022-07-12
JP2019531096A (ja) 2019-10-31
US11243203B2 (en) 2022-02-08
BR112019007424A2 (pt) 2019-07-02
CN110114471A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
MX2016016898A (es) Metodos y composiciones para analisis de muestras.
MX2019004207A (es) Un metodo de diagnostico complementario para el uso en el tratamiento del sindrome de intestino irritable con dietas de intervencion o trasplante de microbiota fecal.
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
MX2015005276A (es) Sistema y metodos para diagnostico de la salud.
WO2011006911A3 (en) Mass spectrometric diagnosis of septicemia
BR112017004899A2 (pt) detecção de proteínas mal dobradas
WO2015157704A3 (en) Methods and compositions for detecting misfolded proteins
MX2010002368A (es) Varolacion rapida de condiciones respiratorias superiores.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
AU2016250096A8 (en) Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016198833A3 (en) Methods for analysing a urine sample
WO2016168359A8 (en) Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
MX2017009752A (es) Adn huesped como biomarcador de la enfermedad de crohn.
CA2982706A1 (en) Automatable method for nucleic acid isolation
SG10201907690TA (en) Device and method for detecting target molecules
WO2014035270A8 (en) A method of identifying gram-negative bacteria using the maldi-tof ms method
EP3502271A3 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers
BR112014007947A2 (pt) método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
EA201401101A1 (ru) Способ лабораторной диагностики пневмонии
GB2519208A (en) Metaproteomic method for diagnosis of bacteriuria, urogenital tract and kidney infections from urinary pellet samples
Abd Al-Mayahi Incidence of Extended-Spectrum β-lactamases ESBLs producing Escherichia coli in patients with urinary tract infection
IN2015DN03988A (es)